News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Optivia Biotechnology Inc. Signs Agreement With U.S. FDA to Assess Role of Dietary Supplements in Drug-Induced Liver Injury


2/1/2011 9:00:33 AM

MENLO PARK, Calif.--(BUSINESS WIRE)--Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced that the company and the U.S. Food and Drug Administration (FDA) have signed a collaboration agreement to assess the effect of dietary supplements on key drug transporters. The goal of the collaboration is to identify potentially harmful drug-dietary supplement interactions, such as an interaction with acetaminophen and other drugs associated with liver toxicity.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES